Retraction notice to: Proteomics-based identification of α-enolase as a potential prognostic marker in cholangiocarcinoma
Ponlapat Yonglitthipagon a,d, Chawalit Pairojkul a,c, Vajarabhongsa Bhudhisawasdi b,c, Jason Mulvenna d, Alex Loukas d, Banchob Sripa a,c
a Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand
b Department of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand
c Liver Fluke and Cholangiocarcinoma Research Center, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand
d Queensland Tropical Health Alliance, James Cook University, Cairns, QLD 4878, Australia
The authors have become aware of a critical oversight and so wish to retract their paper. Figure 1 and Table 1 in the paper published in Clinical Biochemistry are partly similar to a figure and table in their previous publication: Prognostic significance of peroxiredoxin 1 and ezrin–radixin–moesin-binding phosphoprotein 50 in cholangiocarcinoma. Hum Pathol. 2012 Oct.;43a10):1719–30. doi: 10.1016/j.humpath.2011.11.021.
Results for these two papers came from the same experiments but with further characterization of different candidate proteins in the latter paper. Due to a misunderstanding between authors, Fig. 1 showing the 2-D gels fromthe same experimentswas used in both papers. Similarly, Table 1 contains a shared protein list with the previously published paper. The authors have only become aware of these problems recently and so would like to retract the paper from the journal.
The authors apologize sincerely for any inconvenience to readers caused by their error.
DOI of original article: http://dx.doi.org/10.1016/j.clinbiochem.2012.04.004.